PDX Pharma received continued funding from the NCI for PETTRA™ development

PDX Pharma has successfully met the Year 1 milestones of its Phase II SBIR grant (R44CA285233) from the National Cancer Institute (NCI) for the development of PETTRA™ (PLK1 and EGFR Targeted Therapy and Radiation Sensitizer) for lung cancer treatment. As a result, the NCI has issued a Notice of Award for approximately $1.09 million, bringing the total grant funding to $2.4 million. We thank the NCI for its continued support, as well as our dedicated staff and collaborators at OHSU, who worked tirelessly to achieve the project milestones. PETTRA™ demonstrated superior efficacy compared to the standard of care (SOC) in a metastatic non-small cell lung cancer (NSCLC) mouse model and exhibited strong synergy with radiation therapy. In the final phase of the project, we will conduct additional PK/PD and safety studies of PETTRA, advancing it toward clinical trials as both a monotherapy and a radiation sensitizer.

**The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.**